Format

Send to

Choose Destination
Influenza Other Respir Viruses. 2018 Jul;12(4):423-437. doi: 10.1111/irv.12520. Epub 2018 Mar 14.

2015/16 I-MOVE/I-MOVE+ multicentre case-control study in Europe: Moderate vaccine effectiveness estimates against influenza A(H1N1)pdm09 and low estimates against lineage-mismatched influenza B among children.

Author information

1
EpiConcept, Paris, France.
2
National Centre for Microbiology, Instituto de Salud Carlos III, Madrid, Spain.
3
Sorbonne Universités, UPMC Univ Paris 06, INSERM, Institut Pierre Louis d'épidémiologie et de Santé Publique (IPLESP UMRS 1136), Paris, France.
4
Department for Infectious Disease Epidemiology, Robert Koch Institute, Berlin, Germany.
5
Department of Infectious Disease, Istituto Superiore di Sanità, Rome, Italy.
6
National Centre for Epidemiology, Instituto de Salud Carlos III, Madrid, Spain.
7
Ciber Epidemiología y Salud Pública (CIBERESP), Madrid, Spain.
8
National Centre for Epidemiology, Budapest, Hungary.
9
The Public Health Agency of Sweden, Stockholm, Sweden.
10
Health Service Executive - Health Protection Surveillance Centre, Dublin, Ireland.
11
National Institute of Public Health-National Institute of Hygiene, Warsaw, Poland.
12
Centre for Infectious Disease Control, National Institute for Public Health and the Environment, Bilthoven, The Netherlands.
13
Instituto Nacional de Saúde, Dr Ricardo Jorge, Lisbon, Portugal.
14
Development for Microbiology and Immunology, Cantacuzino Institute, National Institute of Research, Bucharest, Romania.
15
Croatian Institute of Public Health, Zagreb, Croatia.
16
Institut Pasteur, Paris, France.
17
National Reference Centre for Influenza, Robert Koch Institute, Berlin, Germany.
18
European Centre for Disease Prevention and Control (ECDC), Stockholm, Sweden.

Abstract

BACKGROUND:

During the 2015/16 influenza season in Europe, the cocirculating influenza viruses were A(H1N1)pdm09 and B/Victoria, which was antigenically distinct from the B/Yamagata component in the trivalent influenza vaccine.

METHODS:

We used the test-negative design in a multicentre case-control study in twelve European countries to measure 2015/16 influenza vaccine effectiveness (VE) against medically attended influenza-like illness (ILI) laboratory-confirmed as influenza. General practitioners swabbed a systematic sample of consulting ILI patients and a random sample of influenza-positive swabs was sequenced. We calculated adjusted VE against influenza A(H1N1)pdm09, A(H1N1)pdm09 genetic group 6B.1 and influenza B overall and by age group.

RESULTS:

We included 11 430 ILI patients, of which 2272 were influenza A(H1N1)pdm09 and 2901 were influenza B cases. Overall VE against influenza A(H1N1)pdm09 was 32.9% (95% CI: 15.5-46.7). Among those aged 0-14, 15-64 and ≥65 years, VE against A(H1N1)pdm09 was 31.9% (95% CI: -32.3 to 65.0), 41.4% (95% CI: 20.5-56.7) and 13.2% (95% CI: -38.0 to 45.3), respectively. Overall VE against influenza A(H1N1)pdm09 genetic group 6B.1 was 32.8% (95% CI: -4.1 to 56.7). Among those aged 0-14, 15-64 and ≥65 years, VE against influenza B was -47.6% (95% CI: -124.9 to 3.1), 27.3% (95% CI: -4.6 to 49.4) and 9.3% (95% CI: -44.1 to 42.9), respectively.

CONCLUSIONS:

Vaccine effectiveness (VE) against influenza A(H1N1)pdm09 and its genetic group 6B.1 was moderate in children and adults, and low among individuals ≥65 years. Vaccine effectiveness (VE) against influenza B was low and heterogeneous among age groups. More information on effects of previous vaccination and previous infection is needed to understand the VE results against influenza B in the context of a mismatched vaccine.

KEYWORDS:

case-control study; influenza; influenza vaccine; multicentre study; vaccine effectiveness

PMID:
29125681
PMCID:
PMC6005601
DOI:
10.1111/irv.12520
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Wiley Icon for PubMed Central
Loading ...
Support Center